The Japanese Ministry of Health, Labour and Welfare has approved AstraZeneca’s Bevespi Aerosphere glycopyrronium/formoterol fumarate MDI for the treatment of COPD, the company said.
Bevespi Aerosphere has been approved for the treatment of COPD in the US since 2016 and in the EU since December 2018. Canada and Australia have also approved the inhaler, which is based on co-suspension technology developed by Pearl Therapeutics. Pearl was acquired by AstraZeneca in 2013.
AstraZeneca Executive VP of BioPharmaceuticals R&D Mene Pangalos commented, “As the first medicine in its class to be approved in a pressurised metered-dose inhaler in Japan, Bevespi Aerosphere offers an important new treatment option and choice of inhaler device for patients with moderate to very severe chronic obstructive pulmonary disease.”
Read the AstraZeneca press release.
